Extended dosage interval of B-cell therapy in multiple sclerosis

Novak, Frederik; Østergaard, Karen; M. Berg, Jonas; Hilt Kristensen, C.; Illés, Zsolt; Sellebjerg, Finn; Sejbæk, Tobias

doi:10.1177/13524585211047080

Public

Extended dosage interval of B-cell therapy in multiple sclerosis

Published in University of Southern Denmark Research Portal (University of Southern Denmark) • Oct 1, 2021

Authors:

Frederik Novak

Karen Østergaard

Jonas M. Berg

Abstract

Introduction: Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of multiple sclerosis (MS). Anti-CD20 therapy causes lysis of B-cells thereby immunosuppression. Safety concerns during the COVID-19 pandemic resulted in paused treatment, thereby prolonged treatment interval. Aims: ...

Subject

Medicine

Ocrelizumab

Multiple sclerosis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!